Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 9/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16126094 | 0.83 | TXNRD1 (0.40) | MAPK1S1PR4MAPTS1PR1NPSR1 | |
| SCHEMBL29391771 | 0.79 | S1PR4 (0.58) | MAPK1S1PR4MAPTS1PR1NPSR1 | |
| SCHEMBL228399 | 0.79 | S1PR4 (0.58) | MAPK1S1PR4MAPTS1PR1NPSR1 | |
| SCHEMBL27227490 | 0.77 | TXNRD1 (0.40) | MAPK1S1PR4MAPTS1PR1NPSR1 | |
| SCHEMBL19100650 | 0.77 | TXNRD1 (0.47) | MAPK1S1PR4MAPTS1PR1NPSR1 | |
| SCHEMBL27227336 | 0.75 | TXNRD1 (0.43) | MAPK1S1PR4MAPTS1PR1NPSR1 | |
| SCHEMBL30271362 | 0.75 | MAOA (0.48) | MAPK1S1PR4MAPTS1PR1NPSR1 | |
| SCHEMBL10654156 | 0.75 | MAOA (0.48) | MAPK1S1PR4MAPTS1PR1NPSR1 | |
| SCHEMBL27226468 | 0.74 | MAPT (0.41) | MAPK1S1PR4MAPTS1PR1NPSR1 | |
| SCHEMBL30526743 | 0.74 | MAPT (0.47) | MAPK1S1PR4MAPTS1PR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940770-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2015-01-27 | — | — | US | disclosed |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2014-03-13 | — | — | US | disclosed |
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | MAPK1 3685/4885S1PR4 2730/4885MAPT 3373/4885 |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | MAPK1 3685/4885S1PR4 2730/4885MAPT 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.